Screening for fetal chromosome abnormalities in the first trimester includes analysis of the serological markers pregnancy-associated plasma protein A (PAPP-A) and free ␤ human choriogonadotropin (free ␤ hCG). The blood sample is traditionally taken around week 12 of gestation, but the performance of earlier blood sampling is not well documented.
RESULTS:
Of 120 cases of trisomy 21, 108 were diagnosed in the first-trimester screening (detection rate 90%). When the blood sample was taken before gestational week 10, the detection rate of trisomy 21 was 97% (70 of 72), whereas 80% were detected (38 of 48) after week 10 ( 2 ϭ 0.0035). For trisomy 18, trisomy 13, and triploidy, 65% (13 of 20) were detected before gestational week 10, and 73% (11 of 15) after (not significant). All 6 cases of triploidy before and after gestational week 10 were detected. The screen positive rate and the maternal age were similar before and after week 10 of gestation.
CONCLUSIONS:
Screening for fetal aneuploidy can be performed with good results with the blood sample taken as early as week 7 of gestation. Blood samples taken before gestational week 10 showed a high detection rate of fetal trisomy 21, with no difference in the detection of fetal trisomy 18, trisomy 13, or triploidy.
First-trimester screening for fetal aneuploidy has been introduced as part of prenatal diagnostics in many countries and has replaced second-trimester screening and age-dependent screening. This shift toward earlier screening has increased the detection rate for fetal aneuploidy and has led to earlier diagnosis and a decrease in the percentage of women undergoing invasive procedures (1, 2 ) . The first-trimester screening is a risk assessment based on age-related risk for fetal aneuploidy, serological markers, pregnancy-associated plasma protein A (PAPP-A), 2 free ␤ human choriogonadotropin (free ␤ hCG), and ultrasound measurement of nuchal translucency. Most studies on firsttrimester screening have used the so-called one-stop clinic to assess risk (OSCAR) approach, where biochemical testing, ultrasound examination, risk assessment, and counseling are performed at a visit at gestational weeks 12-13. Studies have suggested, however, that PAPP-A has increased discriminatory value when taken earlier in the first trimester (3 ), and that the "consecutive combined test"-with the blood sample taken in gestational weeks 8 -13 and the nuchal translucency scan in gestational weeks 11-13-should result in increased detection rates compared to the OSCAR approach (4 -6 ) .
We report here the results of 5 years of experience with the consecutive combined test from a large center of first-trimester screening in Denmark. The study included 44 537 singleton pregnancies with complete first-trimester screening between November 2003 and March 2009. Blood samples were collected between the fifth day of gestational week 7 (7 ϩ 5) and the sixth day of week 13 (13 ϩ 6); nuchal translucency was measured between 11 ϩ 3 and 13 ϩ 6. The screening was performed as a 2-stop approach where the blood sample was drawn by the general practitioner (GP) primarily in gestational weeks 7-10 (see Table 1A ). The samples were centrifuged immediately, and serum was isolated and received at a central laboratory within 24 -48 h. Concentrations of PAPP-A and free ␤ hCG were measured by the Brahms Kryptor method (7 ). Ultrasound scanning was performed according to the guidelines of the Fetal Medicine Foundation (FMF) by sonographers all certified by the FMF, and risk assessment was performed in the Astraia database (Astraia Software Gmbh) using a cutoff at 1:300 at the time of risk assessment for trisomy 21 and 1:150 for trisomy 18 and 13. All pre-and postnatal cases of fetal aneuploidy were verified by the Danish Cytogenetic Registry by karyotyping or PCR. Previous published data show that more than 99% of pregnant women in the County of Aarhus were registered in the Astraia database, proving it as a valid tool for research (1 ) .
Approximately 80% of women had blood samples taken in weeks 8 -10 (Table 1A) , with no statistical overall difference in the screen positive rate between the individual gestational weeks. Analysis of the pooled data for gestational weeks 7-10 vs 11-13, however, showed a significantly lower screen positive rate when the blood sample was taken early ( 2 P ϭ 0.03). We identified 120 cases of pre-and postnatally diagnosed fetal trisomy 21 and 35 cases of fetal trisomy 18, trisomy 13, and triploidy over the study period. Of the cases of fetal trisomy 21, 108 were identified by the screening program. This yields a primary detection rate of 90%. No difference was seen in the mean age of the women or the mean gestational age at time of nuchal translucency scanning between the detected cases of fetal trisomy 21 (35 years) and the missed cases (36 years). Grouping according to gestational age at time of blood sample, however, showed a statistically significant higher detection rate of fetal trisomy 21 when the blood sample was taken before gestational week 10 [70 of 72 cases; mean (CI) 0.97 (0.95-0.99)] vs between gestational ages 10 ϩ 0 and 13 ϩ 6 (38 of 48 cases; 0.79 (0.61-0.91)] ( 2 P ϭ 0.0035) (Table 1B) . No difference in mean age, body weight, or mean gestational age at nuchal translucency scanning was found between the women in the early blood sampling group (35 years, 74 kg, 87 days) and the late sampling group (35 years, 71 kg, 88 days). Thus a significantly increased detection rate by early blood sampling could not be explained by confounding factors affecting the risk assessment. The increased discriminatory value of PAPP-A in gestational weeks 7-10 was documented in the dataset (Fig.  1A) . The distribution of log 10 PAPP-A multiples of the median (MoM) values as a function of gestational age was modeled by the linear regression line for log 10 MoM PAPP-A ϭ 0.0063 ϫ gestational age (days) -0.8289. For free ␤ hCG, the linear regression relationship was log 10 MoM free ␤ hCG ϭ 0.0064 ϫ gestational age (days) -0.2524.
We further identified 35 cases of fetal trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), or triploidy during the study period. Twenty-five of these cases were identified by complete first-trimester screening, with a detection rate of 71%. Including 7 cases that were risk assessed based on either clinical data and biochemistry or clinical data and nuchal translucency scanning gave a detection rate of 76% in the first trimester.
Trisomy 13 and 18 are both associated with deceased concentrations of PAPP-A and free ␤ hCG in maternal serum in the first trimester, whereas concentrations of free ␤ hCG are increased in trisomy 21 (7, 8 ) . However, 2 cases of fetal trisomy 13, 1 case of fetal trisomy 18, and 3 of 6 cases of triploidy were identified by trisomy 21 risk in the Astraia software.
Grouping according to gestational age at time of blood sample showed no statistical difference in the detection rate of trisomy 13, trisomy 18, and triploidy between the group with blood sample before gestational week 10 [14 of 20 cases; proportion (95% CI) The detection rate of trisomy 13 and 18 in gestational weeks 7 and 8, however, was low compared to later in the first trimester. Indeed, the regression lines for log MoM values of fetal trisomy 13 and 18 suggest that the detection rate of these fetal aneuploidies may be lower than later in the first trimester, although more cases are needed to draw a conclusion.
Combined first-trimester risk assessment with blood sampling before gestational week 10 is characterized by significantly increased detection rate of fetal trisomy 21 and similar detection rate of fetal trisomy 18, trisomy 13, and triploidy compared with blood sampling later in the first trimester.
Separation of the blood sampling and the measurement of nuchal translucency make it possible to analyze sera at a centralized laboratory, while allowing nuchal translucency measurement and the posttest counseling to be performed at local ultrasound departments. This is of importance in sparsely populated areas where difficulties in obtaining a critical population mass run counter to the cost efficiency of OSCAR clinics. Our results show that the preanalytical handling of the blood samples for first-trimester screening can be managed by GPs as long as the serum is separated before shipment.
The disadvantage of early blood sampling is the risk that the sample is taken too early in the first trimester. Because the gestational age at time of blood sampling is calculated based on first day of last menstrual period, 6% of the blood samples had to be repeated at 12 weeks, at the time of ultrasound scanning, because the ultrasound indicated an earlier gestational age than that estimated by last menstrual period.
In conclusion, we show that good results can be obtained by screening for fetal aneuploidy using blood samples collected as early as week 7 of gestation. Collecting the blood sample before gestational week 10 gave a high detection rate of fetal trisomy 21, with no decrease in the detection of fetal trisomy 18, trisomy 13, or triploidy. 
